Human hookworm infection is a major cause of gastrointestinal blood loss and iron deficiency anemia, affecting up to one billion people in the developing world.
Single-stage chromogenic assays reveal that AcAP is a highly potent and specific inhibitor of human coagulation, with an intrinsic 14 for the inhibition of free factor Xa of 323.5 pM. In plasma-based clotting time assays, AcAP was more effective at prolonging the prothrombin time than both recombinant hirudin and tick anticoagulant peptide. These data suggest that AcAP, a specific inhibitor of factor Xa, is one of the most potent naturally occurring anticoagulants described to date.
Human hookworm infection is a leading cause of anemia in the tropics and subtropics, affecting nearly one billion people worldwide. Hookworms cause anemia in their host as they feed on blood from capillaries in the lamina propria and submucosa of the small intestine. During this process, each adult hookworm causes up to 0.2 ml of blood loss per day (1) . The effects of chronic hookworm anemia can be devastating, particularly in children, and include severe growth delays and intellectual retardation. Neonatal infection, presumably acquired orally from breast milk of infected mothers, has also been reported to cause acute life-threatening intestinal hemorrhage among newborns in certain hookworm endemic areas (2) .
Like other hematophagous invertebrates, including leeches (3), ticks (4) , and insects (5), hookworms have evolved potent anticlotting strategies to facilitate blood feeding. Both antiplatelet aggregating and anticoagulant activities have been identified (6) (7) (8) in secretory products and homogenates of adult worms. Although the nature of the hookworm anticoagulant has been the subject of scientific investigation for nearly a century, dating back to work by Loeb and Fleisher (9) , the exact mechanism by which these intestinal nematodes interfere with host clotting has not previously been identified.
Recently, we reported that the major anticoagulant activity present in adult Ancylostoma caninum hookworms is attributable to a potent inhibitor of clotting factor Xa (8) . Here we describe the purification, partial amino acid sequence, and biochemical characterization of the A. caninum anticoagulant peptide (AcAP), a hookworm-derived inhibitor of mammalian coagulation.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (10) . Recombinant tick anticoagulant peptide (rTAP) and hirudin (rHIR) were produced as secreted proteins in the methlotropic yeast Pichia pastoris and purified to homogeneity by using ion-exchange chromatography and reverse-phase (rp) HPLC (unpublished data). Both purified recombinant inhibitors were shown to have identical kinetic and physical properties to their counterparts synthesized in Saccharomyces cerevisiae (11, 12) .
MATERIALS AND METHODS
Recombinant human tissue factor (rTF) was produced by a baculovirus expression system and purified to homogeneity by monoclonal antibody affinity chromatography. The rTF apoprotein was incorporated into phospholipid vesicles consisting of phosphatidylcholine, 75% (wt/vol), and phosphatidylserine, 25% (wt/vol) in the presence of detergent as described (13) . For experiments utilizing the prothrombinase complex, phospholipid vesicles contained phosphatidylcholine (67%), phosphatidylglycerol (16%), phosphatidylethanolamine (10%), and phosphatidylserine (7%) without rTF. Phospholipids were purchased from Avanti Polar Lipids.
The following chromogenic substrates were purchased from Kabi Pharmacia Hesper (Franklin, OH): S-2288 (factor VIIa), S-2765 (factor Xa), S-2586 (chymotrypsin), S-2222 (trypsin), S-2302 (kallikrein), S-2366 (plasmin and factor XIa), and S-2444 (urokinase). The substrates Spectrozyme FXIIa (factor XIIa) and Spectrozyme PCa (activated protein C) were from American Diagnostica (Greenwich, CT), and Pefachrome tPA (thrombin and rtPA) was purchased from Centerchem (Tarrytown, NY). All substrates were reconstituted in deionized water prior to use.
Normal human plasma was supplied by George King Biomedical (Overland Park, KS). Simplastin Excel and Platelin L clotting time reagents were purchased from Organon TeknikaCappel. (14) . Starting material for the purification of the hookworm anticoagulant consisted of soluble hookworm protein extracts that had previously been applied to a concanavalin A-Sepharose (Pharmacia) column (14 This assay was also used to determine the apparent equilibrium dissociation inhibitory constant (K:) for purified AcAP against factor Xa. Ratios of inhibited velocity (Vs) to the uninhibited velocity (VO7) were plotted against the corresponding concentration of AcAP. For these experiments, the molar concentration of purified AcAP was determined by quantitative amino acid analysis. Experiments were performed in triplicate and the data were directly fit to an equation for tight-binding inhibitors (17) . Because factor Xa was preequilibrated with AcAP prior to the addition of substrate, the calculated K: represents a thermodynamically appropriate binding constant for the enzyme-inhibitor complex that is independent of the mechanism of inhibition.
Prothrombinase Assay. The inhibitory activity of AcAP was also evaluated against factor Xa contained within the prothrombinase complex. Human factor Va, factor Xa, and phospholipid vesicles were allowed to complex in HBSA with 3 mM CaCl2 for 10 min in a polypropylene test tube. Aliquots of this complex were incubated in wells of a microtiter plate with 4.
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These velocities were plotted against inhibitor concentration and fit to a curve described by a four-parameter equation, yielding an estimated concentration of AcAP (or rTAP) that inhibited prothrombinase complex activity by 50% (IC50).
Serine Protease Specificity. The selectivity of AcAP was examined against 11 serine proteases in addition to factor Xa. Purified AcAP (50 nM) was preincubated with each of the enzymes listed below for 30 min, followed by the addition of the appropriate chromogenic substrate. In a total volume of 200 ,ul in individual wells of a microtiter plate, the final concentrations of the reactants were as follows: factor Xa (0. 
RESULTS
Purification of AcAP. The factor Xa inhibitory activity present in the soluble hookworm extract bound to QSepharose and was eluted in a single peak of activity by a linear gradient of 0-1 M NaCl. As shown in Fig. 1A , the protein fractions containing the anti-factor Xa activity were separated from the majority of protein that eluted from the column. Tryptophan residues were not measured.
After anion exchange, the partially purified anticoagulant was applied to a Superdex 75 HR 10/30 gel-filtration column (Fig.  1B) . The anticoagulant activity migrated with an estimated molecular mass of 15-17 kDa, based on extrapolation from a standard curve constructed with a mixture of proteins of known molecular size (data not shown).
After concentration, the pooled anti-factor Xa activity was subjected to rpHPLC on a C18 column. All of the factor Xa inhibitory activity eluted in a single peak of protein, shown in Fig. 2 . SDS/PAGE under nonreducing conditions of the fraction containing the anti-factor Xa activity revealed a single band with an apparent molecular mass of 16.5 kDa (Fig. 2 Inset). LDMS. LDMS performed on the purified hookworm anticoagulant revealed a single major species with a molecular weight of 8696.7 (Fig. 3) .
Amino Acid Analysis and N-Terminal Amino Acid Sequence. Amino acid analysis was performed on the purified anticoagulant after rpHPLC (Table 1) . Twenty-four of 30 amino acids from the N-terminal end of the molecule were sequenced (Fig. 4) . Amino acid residues 14 (Asp/Val) and 18 (Lys/Gln) could not be distinguished definitively. Screening of three peptide sequence databases revealed that AcAP has no significant amino acid sequence homology to any known serine protease inhibitor or other naturally occurring anticoagulant.
Kinetics of Factor Xa Inhibition by AcAP. By using an equation developed for the analysis of tight binding inhibitors, an intrinsic inhibitory constant (Kr) of 323.5 pM AcAP was determined for the inhibition of free factor Xa (Fig. 5) . This determination of KI is independent of the overall mechanism of inhibition, since the inhibitor and enzyme are preincubated to equilibrium prior to the addition of substrate (17). where Et and It are the total amount of enzyme (factor Xa) and inhibitor (AcAP), respectively, and K: is the intrinsic Kg, irrespective of the mechanism of inhibition (17) .
Prothrombinase Complex Inhibition. The antithrombotic potential of AcAP was also evaluated in assays designed to measure the proteolytic activity of factor Xa against prothrombin, its physiologic substrate. The hookworm anticoagulant significantly inhibited the conversion of prothrombin to thrombin by the prothrombinase complex (factor Xa, factor Va, and phospholipid). AcAP inhibited this complex with an IC50 of 336 pM.
Specificity of Inhibition. The hookworm anticoagulant was tested for inhibition of 11 serine proteases, including those that participate in mammalian coagulation and fibrinolysis. At a concentration of purified AcAP (50 nM) that inhibited the hydrolytic activity of factor Xa by 98%, there was no detectable inhibition of the amidolytic activity of trypsin, chymotrypsin, thrombin, factor VIIa, factor XIIa, kallikrein, plasmin, protein Ca, tPA, and urokinase by using this single-stage chromogenic assay. Factor XIa was inhibited by 55%.
Clotting Time Inhibition. AcAP prolonged both the PT and PTT by using standard clotting time assays (Table 2) . AcAP doubled the PT at 35 nM, which was superior to both rHIR (410 nM) and rTAP (1256 nM). In the activated PTT, the doubling time concentration of AcAP was 85 nM, compared to 32 nM for rHIR and 2365 nM for rTAP.
DISCUSSION
We report here the purification and biochemical characterization of the major anticoagulant from soluble extracts of adult A. caninum hookworms by using a combination of anion-exchange chromatography, size-exclusion chromatograAcAP:
NH2-LYS-ALA-TYR-PRO-GLU-X-GLY-GLU-ASN-GLU-TRP-LEU-ASP- Purified AcAP was compared to rTAP and rHIR by using standard clotting time assays. AcAP was most effective at prolonging the PT, and rHIR had the greatest anticoagulant activity in the activated PTT. AcAP and rHIR were significantly more active than rTAP in both clotting time assays.
phy, and rpHPLC. The purified peptide has a molecular weight of 8697 by LDMS. This is "50% the molecular mass (16.5 kDa) estimated by SDS/PAGE and gel filtration, suggesting that the anticoagulant may migrate as a dimer under nonreducing conditions. The results of SDS/PAGE under reducing conditions were inconclusive, due to the extremely limited quantities of purified AcAP available for these studies.
The sequence obtained from the N-terminal end of AcAP shows no amino acid homology to any described serine protease inhibitor or anticoagulant molecule. Interestingly, the fact that two amino acids (residues 14 and 18, Fig. 4) could not be unambiguously identified suggests that this preparation of AcAP may contain two or more closely related isoforms. This is analogous to the purification of antistasin, the leech salivary factor Xa inhibitor from Haementeria officinalis, for which isoforms differing at two amino acids have been identified (19) . Similar to antistasin, the isoforms of AcAP could not be completely resolved by rpHPLC.
Examination of AcAP's spectrum of inhibition using a single-stage chromogenic assay of protease activity has revealed that this molecule is a specific inhibitor of factor Xa. When tested at a 100-to 200-fold molar excess against 11 other serine proteases with a single-stage chromogenic assay, AcAP showed only limited inhibition (55%) of factor XIa. Although the in vivo significance of this factor XIa inhibition is unknown, when repeated with equimolar concentrations of AcAP and enzyme, only factor Xa is affected, while no inhibition of factor XIa is detected.
The inhibition of factor Xa by AcAP obeys tight-binding kinetics. As shown in Fig. 5 , the data for free factor Xa inhibition adequately fits the Morrison equation for slow tight-binding inhibitors. This characteristic is consistently shared by other naturally occurring anticoagulant molecules, including TAP, HIR, and antistasin, all of which stoichiometrically inhibit their target enzymes.
In addition to its potent inhibition of free factor Xa (K:i, 323.5 pM), AcAP was also effective at inhibiting the activity of factor Xa contained within the prothrombinase complex, composed of factors Xa and Va complexed to phospholipid vesicles. In this assay, the IC50 value for AcAP's inhibition of factor Xa against its physiologic substrate, prothrombin, was 336 pM. This IC50 value is somewhat greater than that derived under identical conditions for rTAP (25 pM), the factor Xa inhibitor isolated from the tick Ornithodoros moubata.
In standard clotting time assays (Table 2) , AcAP prolonged both the PT and PTT in a concentration-dependent fashion, with doubling time concentrations of 35 nM (PT) and 85 nM (activated PTT), respectively. AcAP exhibited its most dramatic effect on the PT, in which it was significantly more potent than either rTAP or rHIR. While AcAP was somewhat less effective than rHIR with regard to prolongation of the activated PTT, both were significantly more potent than rTAP. The difference between rTAP and AcAP in these clotting time assays is not consistent with their inhibition of free Xa and prothrombinase complex activity in vitro. This may be explained by the fact that the modest effect of rTAP on clotting times reflects its relatively slow onset of inhibition of factor Xa (20) and suggests that AcAP may have a more rapid onset of inhibition. Based on the clotting time data presented here, AcAP appears to be one of the most potent antithrombotic molecules identified to date.
We postulate that interfering with the ability of adult hookworms to feed on host blood may significantly lessen the morbid effects of chronic hookworm infestation. AcAP, because it is such a potent antihemostatic agent, represents a reasonable target for such a strategy. In addition, because of its potent and specific anticoagulant activity, AcAP warrants further evaluation as a potential therapeutic antithrombotic agent.
